Gyre Therapeutics(GYRE) - 2025 Q1 - Quarterly Results

SAN DIEGO, May 9, 2025 (GLOBE NEWSWIRE) – Gyre Therapeutics ("Gyre") (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced financial results for the first quarter ended March 31, 2025 and provided a business update. "This quarter marked a meaningful step forward in expanding our market presence, particularly in the liver space," said Han Ying, Ph.D., CEO of Gyre Therapeutics. "The successful launch of avatrombopag and our growing commercial footprin ...